OncoMatch/Clinical Trials/NCT03295981
Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone
Is NCT03295981 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Zoledronic Acid for giant cell tumor of bone.
Treatment: Zoledronic Acid — The purpose of the clinical study is to investigate whether the local delivery of bisphosphonate as a surgical adjuvant can decrease the chance of a giant cell tumor of bone coming back to the same location. The hypothesis is that the local administration of bisphosphonate will decrease the rate of the tumor returning compared to traditional aggressive surgical removal of the tumor.
Check if I qualifyExtracted eligibility criteria
Prior therapy
Cannot have received: bisphosphonate
No previous systemic bisphosphonate or denosumab therapy; Previous systemic bisphosphonate or denosumab therapy [excluded]
Cannot have received: RANKL inhibitor (denosumab)
No previous systemic bisphosphonate or denosumab therapy; Previous systemic bisphosphonate or denosumab therapy [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California - Los Angeles · Los Angeles, California
- Indiana University · Indianapolis, Indiana
- University of Iowa · Iowa City, Iowa
- University of Kansas · Overland Park, Kansas
- Johns Hopkins University Hospital · Baltimore, Maryland
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify